Clinical Trial Update: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pembrolizumab followed by maintenance olaparib with first-line chemotherapy in BRCA non-mutated advanced epithelial ovarian cancer. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Neoplasms

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-12